Recombinant Human ABCB1 Protein (HEK293)，Flag

ABCB1, also known as P-glycoprotein, is a key member of the ATP-binding cassette (ABC) transporter family, playing a crucial role in the pharmacokinetics and bioavailability of numerous drugs. Its expression is often associated with multidrug resistance (MDR) in cancer cells, where it actively mediates the efflux of a variety of therapeutic agents, thereby reducing their intracellular concentrations and efficacy. Understanding the structure and function of ABCB1 is essential for developing strategies to overcome MDR, improve drug delivery, and enhance treatment outcomes in cancer therapy. The study of recombinant ABCB1 proteins has gained significant attention in recent years, as it enables researchers to investigate the biochemical properties of this transporter in a controlled setting. By expressing recombinant ABCB1 in heterologous systems, such as yeast or mammalian cells, scientists can elucidate its substrate specificity, regulatory mechanisms, and interactions with inhibitors and potentiators. These insights contribute to the design of novel therapeutics that can circumvent ABCB1-mediated drug resistance and offer improved clinical efficacy. Furthermore, recombinant ABCB1 models serve as valuable tools for high-throughput screening of drug candidates and for studying the intricacies of drug-transporter interactions, paving the way for personalized medicine approaches in oncology and other therapeutic areas.